Sign Up Today and Learn More About Storm Therapeutics Stock
Invest in or calculate the value of your shares in Storm Therapeutics or other pre-IPO companies through EquityZen's platform.
Storm Therapeutics Stock (STOT)
Targeting pathways that modify RNA to deliver novel cancer therapeutics
About Storm Therapeutics Stock
Founded
2015
Industries
Software, Artificial Intelligence, Data and Analytics
Storm Therapeutics Press Mentions
Stay in the know about the latest news on Storm Therapeutics
Storm Therapeutics, Alida Biosciences Partner to Develop RNA Modification-Based Cancer Therapies
genomeweb • Jan 09, 2026
STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications
pharmiweb • Jan 09, 2026
STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications
sdbn • Jan 09, 2026
Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
pharmatimes • Jan 09, 2026
STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications
prnewswire • Jan 08, 2026
Storm Therapeutics Management
Leadership team at Storm Therapeutics
Board of Directors
Sakae Asanuma
Board Member
Hakan Goker
Join now and verify your accreditation status to gain access to:
- Storm Therapeutics Current Valuation
- Storm Therapeutics Stock Price
- Storm Therapeutics Management
- Available deals in Storm Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Storm Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Storm Therapeutics Revenue and Financials
- Storm Therapeutics Highlights
- Storm Therapeutics Business Model
- Storm Therapeutics Risk Factors
- Storm Therapeutics Research Report from SACRA Research
Trading Storm Therapeutics Stock
How to invest in Storm Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Storm Therapeutics through EquityZen funds. These investments are made available by existing Storm Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Storm Therapeutics stock?
Shareholders can sell their Storm Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 430K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 52K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
